Advisory Board

Mark Krul, Chairman
Mark Krul, Chairman, Ph.D.

Prior to founding Aglaia BioMedical Ventures and Aglaia Oncology Fund, Mark Krul held several positions at NDDO Oncology BV (formerly the EORTC New Drug Development Office) in the field of oncology drug development strategies. Before that, Mark Krul was Research Manager of the European Cancer Center and Head of the Department of Molecular Virology at the National Institute of Public Health and Environmental Protection, the Netherlands. Mark initiated in 1989 a European Concerted Action (25 European centers) on “Immunology of HPV and Vaccine Development”, which also was the topic of his Ph.D. thesis. He has a background in molecular biology and immunology and over 20 years of experience in anti-cancer drug development. Mark Krul and his colleagues of Aglaia are founders of ISA Pharmaceuticals.

Alex Eggermont, M.D., Ph.D.

Alex Eggermont, M.D., Ph.D., is General Director of the Institut de Cancérologie Gustave Roussy (IGR, Villejuif) and a Professor of Surgical Oncology at Rotterdam’s Erasmus University (Netherlands). Prof. Eggermont specializes in preclinical and clinical / translational oncology, and is a specialist in immunotherapy research and the treatment of melanomas and sarcomas.

Ulrich Granzer, Ph.D.

Ulrich Granzer, Ph.D., is a pharmacist and founder of Granzer Regulatory Consulting & Services. In addition, he is a founding member and President of the Board of the German Association of Regulatory Affairs (DGRA). He has long-standing experience in all regulatory aspects of the pharmaceutical industry from his time at Glaxo (now GSK), BASF, Pharma / Knoll, and Bayer. At Bayer, as Vice President of Global Regulatory Affairs he was responsible for all regulatory aspects of the development and submission of projects worldwide. Dr. Granzer’s expertise in regulatory affairs extends to both U.S. (FDA) and European (EMA) regulatory authorities.

Drew M. Pardoll, M.D., Ph.D.

Drew M. Pardoll, M.D., Ph.D., is a cancer immunologist and an Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University School of Medicine. He is also Director of Cancer Immunology at the Sidney Kimmel Comprehensive Cancer Center. Dr. Pardoll specializes in cancer immunology and cancer immunotherapy and has contributed to the development of many immunotherapies.

Sjoerd H. van der Burg, Ph.D.

Sjoerd H. van der Burg, Ph.D. is a Professor in Experimental Cancer Immunology and Therapy at the Department of Clinical Oncology of the Leiden University Medical Center. He has extensive experience in tumor immunology and the immunotherapy of cancer, in particular the development of therapeutic vaccine strategies and the adoptive transfer of ex-vivo expanded T cells. He is specialized in the immunomonitoring of human T cell responses and is the current Chair of the Association for Cancer Immunotherapy Immunoguiding Program (CIP).